<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36982693</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>6</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>15</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Dopamine Transmission Imbalance in Neuroinflammation: Perspectives on Long-Term COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">5618</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24065618</ELocationID><Abstract><AbstractText>Dopamine (DA) is a key neurotransmitter in the basal ganglia, implicated in the control of movement and motivation. Alteration of DA levels is central in Parkinson's disease (PD), a common neurodegenerative disorder characterized by motor and non-motor manifestations and deposition of alpha-synuclein (&#x3b1;-syn) aggregates. Previous studies have hypothesized a link between PD and viral infections. Indeed, different cases of parkinsonism have been reported following COVID-19. However, whether SARS-CoV-2 may trigger a neurodegenerative process is still a matter of debate. Interestingly, evidence of brain inflammation has been described in postmortem samples of patients infected by SARS-CoV-2, which suggests immune-mediated mechanisms triggering the neurological sequelae. In this review, we discuss the role of proinflammatory molecules such as cytokines, chemokines, and oxygen reactive species in modulating DA homeostasis. Moreover, we review the existing literature on the possible mechanistic interplay between SARS-CoV-2-mediated neuroinflammation and nigrostriatal DAergic impairment, and the cross-talk with aberrant &#x3b1;-syn metabolism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mancini</LastName><ForeName>Maria</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2181-7485</Identifier><AffiliationInfo><Affiliation>Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Mondino Foundation, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natoli</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-3758-5375</Identifier><AffiliationInfo><Affiliation>Department of Clinical Science and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Maugeri Pavia, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gardoni</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-4598-5563</Identifier><AffiliationInfo><Affiliation>Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Luca</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pharmacological and Biomolecular Sciences "Rodolfo Paoletti", University of Milan, 20133 Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pisani</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8432-594X</Identifier><AffiliationInfo><Affiliation>Department of Brain and Behavioral Sciences, University of Pavia, 27100 Pavia, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>IRCCS Mondino Foundation, 27100 Pavia, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ID 3433068</GrantID><Agency>Fondazione Regionale per la Ricerca Biomedica, Regione Lombardia</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051844">alpha-Synuclein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000090862" MajorTopicYN="N">Neuroinflammatory Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051844" MajorTopicYN="N">alpha-Synuclein</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">alpha-synuclein</Keyword><Keyword MajorTopicYN="N">cytokines</Keyword><Keyword MajorTopicYN="N">dopamine</Keyword><Keyword MajorTopicYN="N">dopamine release</Keyword><Keyword MajorTopicYN="N">glia</Keyword><Keyword MajorTopicYN="N">interleukins</Keyword><Keyword MajorTopicYN="N">long-COVID</Keyword><Keyword MajorTopicYN="N">neuroinflammation</Keyword><Keyword MajorTopicYN="N">post-acute sequelae</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>3</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36982693</ArticleId><ArticleId IdType="pmc">PMC10056044</ArticleId><ArticleId IdType="doi">10.3390/ijms24065618</ArticleId><ArticleId IdType="pii">ijms24065618</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greenhalgh A.D., David S., Bennett F.C. Immune cell regulation of glia during CNS injury and disease. Nat. Rev. Neurosci. 2020;21:139&#x2013;152. doi: 10.1038/s41583-020-0263-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-020-0263-9</ArticleId><ArticleId IdType="pubmed">32042145</ArticleId></ArticleIdList></Reference><Reference><Citation>Fani Maleki A., Rivest S. Innate immune cells: Monocytes, monocyte-derived macrophages and microglia as therapeutic target for Alzheimer&#x2019;s disease and multiple sclerosis. Front. Cell Neurosci. 2019;13:355. doi: 10.3389/fncel.2019.00355.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2019.00355</ArticleId><ArticleId IdType="pmc">PMC6690269</ArticleId><ArticleId IdType="pubmed">31427930</ArticleId></ArticleIdList></Reference><Reference><Citation>Vainchtein I.D., Molofsky A.V. Astrocytes and microglia: In sickness and in health. Trends Neurosci. 2020;43:144&#x2013;154. doi: 10.1016/j.tins.2020.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2020.01.003</ArticleId><ArticleId IdType="pmc">PMC7472912</ArticleId><ArticleId IdType="pubmed">32044129</ArticleId></ArticleIdList></Reference><Reference><Citation>Xanthos D.N., Sandk&#xfc;hler J. Neurogenic inflammation: Inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci. 2014;15:43&#x2013;53. doi: 10.1038/nrn3617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn3617</ArticleId><ArticleId IdType="pubmed">24281245</ArticleId></ArticleIdList></Reference><Reference><Citation>Habbas S., Santello M., Becker D., Stubbe H., Zappia G., Liaudet N., Klaus F.R., Kollias G., Fontana A., Pryce C.R., et al. Neuroinflammatory TNF&#x3b1; impairs memory via astrocyte signaling. Cell. 2015;163:1730&#x2013;1741. doi: 10.1016/j.cell.2015.11.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2015.11.023</ArticleId><ArticleId IdType="pubmed">26686654</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheridan G.K., Murphy K.J. Neuron-glia crosstalk in health and disease: Fractalike and CX3CR1 take centre stage. Open Biol. 2013;3:130181. doi: 10.1098/rsob.130181.</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsob.130181</ArticleId><ArticleId IdType="pmc">PMC3877844</ArticleId><ArticleId IdType="pubmed">24352739</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn A.J. Effects of cytokines and infections on brain neurochemistry. Clin. Neurosci. Res. 2006;6:52&#x2013;68. doi: 10.1016/j.cnr.2006.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cnr.2006.04.002</ArticleId><ArticleId IdType="pmc">PMC2136407</ArticleId><ArticleId IdType="pubmed">18079991</ArticleId></ArticleIdList></Reference><Reference><Citation>Emmi A., Rizzo S., Barzon L., Sandre M., Carturan E., Sinigaglia A., Riccetti S., Della Barbera M., Boscolo-Berto R., Cocco P., et al. Detection of SARS-CoV-2 viral proteins and genomic sequences in human brainstem nuclei. NPJ Parkinsons Dis. 2023;9:25. doi: 10.1038/s41531-023-00467-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41531-023-00467-3</ArticleId><ArticleId IdType="pmc">PMC9924897</ArticleId><ArticleId IdType="pubmed">36781876</ArticleId></ArticleIdList></Reference><Reference><Citation>Boura I., Chaudhuri K.R. Coronavirus disease 2019 and related parkinsonism: The clinical evidence thus far. Mov. Disord. Clin. Pract. 2022;9:584&#x2013;593. doi: 10.1002/mdc3.13461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mdc3.13461</ArticleId><ArticleId IdType="pmc">PMC9111006</ArticleId><ArticleId IdType="pubmed">35601258</ArticleId></ArticleIdList></Reference><Reference><Citation>Calculli A., Bocci T., Porcino M., Avenali M., Casellato C., Priori A., Pisani A. Parkinson&#x2019;s disease following COVID-19: Six cases report. Eur. J. Neurol. 2023 doi: 10.1111/ene.15732. ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.15732</ArticleId><ArticleId IdType="pubmed">36807419</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda W., Furuta T., Nakamura K.C., Hioki H., Fujiyama F., Arai R., Kaneko T. Single nigrostriatal dopaminergic neurons form widely spread and highly dense axonal arborizations in the neostriatum. J. Neurosci. 2009;29:444&#x2013;453. doi: 10.1523/JNEUROSCI.4029-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.4029-08.2009</ArticleId><ArticleId IdType="pmc">PMC6664950</ArticleId><ArticleId IdType="pubmed">19144844</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice M.E., Cragg S.J., Greenfield S.A. Characteristics of electrically evoked somatodendritic dopamine release in substantia nigra and ventral tegmental area in vitro. J. Neurophysiol. 1997;77:853&#x2013;862. doi: 10.1152/jn.1997.77.2.853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.1997.77.2.853</ArticleId><ArticleId IdType="pubmed">9065854</ArticleId></ArticleIdList></Reference><Reference><Citation>Cragg S.J. Variable dopamine release probability and short-term plasticity between functional domains of the primate striatum. J. Neurosci. 2003;23:4378&#x2013;4385. doi: 10.1523/JNEUROSCI.23-10-04378.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-10-04378.2003</ArticleId><ArticleId IdType="pmc">PMC6741072</ArticleId><ArticleId IdType="pubmed">12764127</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D., Cragg S.J., Rice M.E. Striatal dopamine neurotransmission: Regulation of release and uptake. Basal. Ganglia. 2016;6:123&#x2013;148. doi: 10.1016/j.baga.2016.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.baga.2016.02.001</ArticleId><ArticleId IdType="pmc">PMC4850498</ArticleId><ArticleId IdType="pubmed">27141430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.T., Rice M.E. Novel Ca2+ dependence and time course of somatodendritic dopamine release: Substantia nigra versus striatum. J. Neurosci. 2001;21:7841&#x2013;7847. doi: 10.1523/JNEUROSCI.21-19-07841.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.21-19-07841.2001</ArticleId><ArticleId IdType="pmc">PMC6762877</ArticleId><ArticleId IdType="pubmed">11567075</ArticleId></ArticleIdList></Reference><Reference><Citation>Brimblecombe K.R., Gracie C.J., Platt N.J., Cragg S.J. Gating of dopamine transmission by calcium and axonal N-, Q-, T-, and L-type voltage-gated calcium channels differs between striatal domains. J. Physiol. 2015;593:929&#x2013;946. doi: 10.1113/jphysiol.2014.285890.</Citation><ArticleIdList><ArticleId IdType="doi">10.1113/jphysiol.2014.285890</ArticleId><ArticleId IdType="pmc">PMC4398530</ArticleId><ArticleId IdType="pubmed">25533038</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen B.T., Moran K.A., Avshalumov M.V., Rice M.E. Limited regulation of somatodendritic dopamine release by voltage-sensitive Ca channels contrasted with strong regulation of axonal dopamine release. J. Neurochem. 2006;96:645&#x2013;655. doi: 10.1111/j.1471-4159.2005.03519.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03519.x</ArticleId><ArticleId IdType="pubmed">16405515</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Kaeser P.S. Mechanisms and regulation of dopamine release. Curr. Opin. Neurobiol. 2019;57:46&#x2013;53. doi: 10.1016/j.conb.2019.01.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.conb.2019.01.001</ArticleId><ArticleId IdType="pmc">PMC6629510</ArticleId><ArticleId IdType="pubmed">30769276</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu C., Goel P., Kaeser P.S. Spatial and temporal scales of dopamine transmission. Nat. Rev. Neurosci. 2021;22:345&#x2013;358. doi: 10.1038/s41583-021-00455-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41583-021-00455-7</ArticleId><ArticleId IdType="pmc">PMC8220193</ArticleId><ArticleId IdType="pubmed">33837376</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira D.B., Sulzer D. Mechanisms of dopamine quantal size regulation. Front. Biosci. 2012;17:2740&#x2013;2767. doi: 10.2741/4083.</Citation><ArticleIdList><ArticleId IdType="doi">10.2741/4083</ArticleId><ArticleId IdType="pubmed">22652810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pothos E.N., Larsen K.E., Krantz D.E., Liu Y., Haycock J.W., Setlik W., Gershon M.D., Edwards R.H., Sulzer D. Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J. Neurosci. 2000;20:7297&#x2013;7306. doi: 10.1523/JNEUROSCI.20-19-07297.2000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.20-19-07297.2000</ArticleId><ArticleId IdType="pmc">PMC6772799</ArticleId><ArticleId IdType="pubmed">11007887</ArticleId></ArticleIdList></Reference><Reference><Citation>Omiatek D.M., Bressler A.J., Cans A.S., Andrews A.M., Heien M.L., Ewing A.G. The real catecholamine content of secretory vesicles in the CNS revealed by electrochemical cytometry. Sci. Rep. 2013;3:1447. doi: 10.1038/srep01447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep01447</ArticleId><ArticleId IdType="pmc">PMC3596796</ArticleId><ArticleId IdType="pubmed">23486177</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartier E.A., Parra L.A., Baust T.B., Quiroz M., Salazar G., Faundez V., Ega&#xf1;a L., Torres G.E. A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J. Biol. Chem. 2010;285:1957&#x2013;1966. doi: 10.1074/jbc.M109.054510.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M109.054510</ArticleId><ArticleId IdType="pmc">PMC2804354</ArticleId><ArticleId IdType="pubmed">19903816</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J.M., Hanson G.R., Fleckenstein A.E. Regulation of the vesicular monoamine transporter-2: A novel mechanism for cocaine and other psychostimulants. J. Pharmacol. Exp. Ther. 2001;296:762&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pubmed">11181904</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate redistributes vesicular monoamine transporter-2: Role of dopamine receptors. J. Neurosci. 2002;22:8705&#x2013;8710. doi: 10.1523/JNEUROSCI.22-19-08705.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-19-08705.2002</ArticleId><ArticleId IdType="pmc">PMC6757793</ArticleId><ArticleId IdType="pubmed">12351745</ArticleId></ArticleIdList></Reference><Reference><Citation>Sandoval V., Riddle E.L., Hanson G.R., Fleckenstein A.E. Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficits. J. Pharmacol. Exp. Ther. 2003;304:1181&#x2013;1187. doi: 10.1124/jpet.102.045005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.102.045005</ArticleId><ArticleId IdType="pubmed">12604695</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirenberg M.J., Chan J., Liu Y., Edwards R.H., Pickel V.M. Ultrastructural localization of the vesicular monoamine transporter-2 in midbrain dopaminergic neurons: Potential sites for somatodendritic storage and release of dopamine. J. Neurosci. 1996;16:4135&#x2013;4145. doi: 10.1523/JNEUROSCI.16-13-04135.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.16-13-04135.1996</ArticleId><ArticleId IdType="pmc">PMC6579002</ArticleId><ArticleId IdType="pubmed">8753875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaeser P.S., Regehr W.G. Molecular mechanisms for synchronous, asynchronous, and spontaneous neurotransmitter release. Annu. Rev. Physiol. 2014;76:333&#x2013;363. doi: 10.1146/annurev-physiol-021113-170338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-physiol-021113-170338</ArticleId><ArticleId IdType="pmc">PMC4503208</ArticleId><ArticleId IdType="pubmed">24274737</ArticleId></ArticleIdList></Reference><Reference><Citation>Pang Z.P., S&#xfc;dhof T.C. Cell biology of Ca2+-triggerd exocytosis. Curr. Opin. Cell Biol. 2010;22:496&#x2013;505. doi: 10.1016/j.ceb.2010.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ceb.2010.05.001</ArticleId><ArticleId IdType="pmc">PMC2963628</ArticleId><ArticleId IdType="pubmed">20561775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist F., Niazi H.S., Nissbrandt H. Evidence for different exocytosis pathways in dendritic and terminal dopamine release in vivo. Brain Res. 2002;950:245&#x2013;453. doi: 10.1016/S0006-8993(02)03047-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(02)03047-0</ArticleId><ArticleId IdType="pubmed">12231250</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkovsky P., Patel J.C., Lee C.R., Rice M.E. Immunocytochemical identification of proteins involved in dopamine release from somatodendritic compartment of nigral dopaminergic neurons. Neuroscience. 2009;164:488&#x2013;496. doi: 10.1016/j.neuroscience.2009.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2009.08.017</ArticleId><ArticleId IdType="pmc">PMC2879289</ArticleId><ArticleId IdType="pubmed">19682556</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendez J.A., Bourque M.J., Fasano C., Kortleven C., Trudeau L.E. Somatodendritic dopamine release requires synaptotagmin 4 and 7 and the participation of voltage-gated calcium channels. J. Biol. Chem. 2011;286:23928&#x2013;23937. doi: 10.1074/jbc.M111.218032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.218032</ArticleId><ArticleId IdType="pmc">PMC3129174</ArticleId><ArticleId IdType="pubmed">21576241</ArticleId></ArticleIdList></Reference><Reference><Citation>Burr&#xe9; J., Sharma M., Tsetsenis T., Buchman V., Etherton M.R., S&#xfc;dhof T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science. 2010;329:1663&#x2013;1667. doi: 10.1126/science.1195227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1195227</ArticleId><ArticleId IdType="pmc">PMC3235365</ArticleId><ArticleId IdType="pubmed">20798282</ArticleId></ArticleIdList></Reference><Reference><Citation>Tritsch N.X., Sabatini B.L. Dopaminergic modulation of synaptic transmission in cortex and striatum. Neuron. 2012;76:33&#x2013;50. doi: 10.1016/j.neuron.2012.09.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2012.09.023</ArticleId><ArticleId IdType="pmc">PMC4386589</ArticleId><ArticleId IdType="pubmed">23040805</ArticleId></ArticleIdList></Reference><Reference><Citation>Palij P., Bull D.R., Sheehan M.J., Millar J., Stamford J., Kruk Z.L., Humphrey P.P. Presynaptic regulation of dopamine release in corpus striatum monitored in vitro and in real time by fast cyclic voltammetry. Brain Res. 1990;509:172&#x2013;174. doi: 10.1016/0006-8993(90)90329-A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(90)90329-A</ArticleId><ArticleId IdType="pubmed">2137719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull D.R., Sheehan M.J. Presynaptic regulation of electrically evoked dopamine overflow in nucleus accumbens: A pharmacological study using fast scan cyclic voltammetry in vitro. Naunyn Schmiedebergs Arch. Pharmacol. 1991;343:260&#x2013;265. doi: 10.1007/BF00251124.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00251124</ArticleId><ArticleId IdType="pubmed">1678139</ArticleId></ArticleIdList></Reference><Reference><Citation>Beckstead M.J., Grandy D.K., Wickman K., Williams J.T. Vesicular dopamine release elicits an inhibitory postsynaptic current in midbrain dopamine neurons. Neuron. 2004;42:939&#x2013;946. doi: 10.1016/j.neuron.2004.05.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2004.05.019</ArticleId><ArticleId IdType="pubmed">15207238</ArticleId></ArticleIdList></Reference><Reference><Citation>Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J. Neurosci. 1996;16:436&#x2013;447. doi: 10.1523/JNEUROSCI.16-02-00436.1996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.16-02-00436.1996</ArticleId><ArticleId IdType="pmc">PMC6578661</ArticleId><ArticleId IdType="pubmed">8551328</ArticleId></ArticleIdList></Reference><Reference><Citation>German C.L., Baladi M.G., McFadden L.M., Hanson G.R., Fleckenstein A.E. Regulation of the dopamine and vesicular monoamine transporters: Pharmacological targets and implications for disease. Pharmacol. Rev. 2015;67:1005&#x2013;1024. doi: 10.1124/pr.114.010397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/pr.114.010397</ArticleId><ArticleId IdType="pmc">PMC4630566</ArticleId><ArticleId IdType="pubmed">26408528</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz Y., Benoit-Marand M., Gonon F., Sulzer D. Presynaptic regulation of dopaminergic neurotransmission. J. Neurochem. 2003;87:273&#x2013;289. doi: 10.1046/j.1471-4159.2003.02050.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.02050.x</ArticleId><ArticleId IdType="pubmed">14511105</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulley J.M., Zahnizer N.R. Rapid regulation of dopamine transporter function by substrates, blockers, and presynaptic receptor ligands. Eur. J. Pharmacol. 2003;479:139&#x2013;152. doi: 10.1016/j.ejphar.2003.08.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2003.08.064</ArticleId><ArticleId IdType="pubmed">14612145</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitt K.C., Reith M.E. Regulation of the dopamine transporter: Aspects relevant to psychostimulant drugs of abuse. Ann. N. Y. Acad. Sci. 2010;1187:316&#x2013;340. doi: 10.1111/j.1749-6632.2009.05148.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.05148.x</ArticleId><ArticleId IdType="pubmed">20201860</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Rao Z. Structural biology of SARS-CoV-2 and implications for therapeutic development. Nat. Rev. Microbiol. 2021;19:685&#x2013;700. doi: 10.1038/s41579-021-00630-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-021-00630-8</ArticleId><ArticleId IdType="pmc">PMC8447893</ArticleId><ArticleId IdType="pubmed">34535791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann M., Kleine-Weber H., Schroeder S., Kr&#xfc;ger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., et al. SARS-CoV-2 cell entry depends on ACE2 and TMRPSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181:271&#x2013;280. doi: 10.1016/j.cell.2020.02.052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.052</ArticleId><ArticleId IdType="pmc">PMC7102627</ArticleId><ArticleId IdType="pubmed">32142651</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Shafiei M.S., Longoria C., Schoggins J.W., Savani R.C., Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the NF-&#x3ba;B pathway. eLife. 2021;10:e68563. doi: 10.7554/eLife.68563.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.68563</ArticleId><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor M.P., Enquist L.W. Axonal spread of neuroinvasive viral infections. Trends Microbiol. 2015;23:283&#x2013;288. doi: 10.1016/j.tim.2015.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tim.2015.01.002</ArticleId><ArticleId IdType="pmc">PMC4417403</ArticleId><ArticleId IdType="pubmed">25639651</ArticleId></ArticleIdList></Reference><Reference><Citation>Harschnitz O., Studer L. Human stem cell models to study host-virus interactions in the central nervous system. Nat. Rev. Immunol. 2021;21:441&#x2013;453. doi: 10.1038/s41577-020-00474-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-00474-y</ArticleId><ArticleId IdType="pmc">PMC9653304</ArticleId><ArticleId IdType="pubmed">33398129</ArticleId></ArticleIdList></Reference><Reference><Citation>Iroeglu J.D., Ifenatuoha C.W., Ijomone O.M. Potential neurological impact of coronaviruses: Implications for the novel SARS-CoV-2. Neurol. Sci. 2020;41:1329&#x2013;1337. doi: 10.1007/s10072-020-04469-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-020-04469-4</ArticleId><ArticleId IdType="pmc">PMC7232928</ArticleId><ArticleId IdType="pubmed">32424503</ArticleId></ArticleIdList></Reference><Reference><Citation>Pellegrini L., Albecka A., Mallery D.L., Kellner M.J., Paul D., Carter A.P., James L.C., Lancaster M.A. SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids. Cell Stem Cell. 2020;27:951&#x2013;961. doi: 10.1016/j.stem.2020.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.10.001</ArticleId><ArticleId IdType="pmc">PMC7553118</ArticleId><ArticleId IdType="pubmed">33113348</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein S.R., Ramelli S.C., Grazioli A., Chung J.Y., Singh M., Yinda C.K., Winkler C.W., Sun J., Dickey J.M., Ylaya K., et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature. 2022;612:758&#x2013;763. doi: 10.1038/s41586-022-05542-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-05542-y</ArticleId><ArticleId IdType="pmc">PMC9749650</ArticleId><ArticleId IdType="pubmed">36517603</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Han Y., Nilsson-Payant B.E., Gupta V., Wang P., Duan X., Tang X., Zhu J., Zhao Z., Jaffr&#xe9; F., et al. A human pluripotent stem cell-based platform to study SARS-CoV-2 tropism and model virus infection in human cells and organoids. Cell Stem Cell. 2020;27:125&#x2013;136.e7. doi: 10.1016/j.stem.2020.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.06.015</ArticleId><ArticleId IdType="pmc">PMC7303620</ArticleId><ArticleId IdType="pubmed">32579880</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacob F., Pather S.R., Huang W.K., Zhang F., Wong S.Z.H., Zhou H., Cubitt B., Fan W., Chen C.Z., Xu M., et al. Human pluripotent stem cell-derived neural cells and brain organoids reveal SARS-CoV-2 neurotropism predominates in choroid plexus epithelium. Cell Stem Cell. 2020;27:937&#x2013;950.e9. doi: 10.1016/j.stem.2020.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.stem.2020.09.016</ArticleId><ArticleId IdType="pmc">PMC7505550</ArticleId><ArticleId IdType="pubmed">33010822</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E., Zhang C., Israelow B., Lu-Calligan A., Vietes Prado A., Skriabine S., Lu P., Weizman O.E., Liu F., Dai Y., et al. Neuroinvasion of SARS-CoV-2 in human and mouse brain. J. Exp. Med. 2021;218:e20202135. doi: 10.1084/jem.20202135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20202135</ArticleId><ArticleId IdType="pmc">PMC7808299</ArticleId><ArticleId IdType="pubmed">33433624</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R., Wang K., Yu J., Howard D., French L., Chen Z., Wen C., Xu Z. The spatial and cell-type distribution of SARS-CoV-2 receptor ACE2 in the human and mouse brains. Front. Neurol. 2021;11:573095. doi: 10.3389/fneur.2020.573095.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2020.573095</ArticleId><ArticleId IdType="pmc">PMC7855591</ArticleId><ArticleId IdType="pubmed">33551947</ArticleId></ArticleIdList></Reference><Reference><Citation>Cantuti-Castelvetri L., Ojha R., Pedro L.D., Djannatian M., Franz J., Kuivanen S., van der Meer F., Kallio K., Kaya T., Anastasina M., et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. Science. 2020;370:856&#x2013;860. doi: 10.1126/science.abd2985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd2985</ArticleId><ArticleId IdType="pmc">PMC7857391</ArticleId><ArticleId IdType="pubmed">33082293</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons G., Gosalia D.N., Rennekamp A.J., Reeves A.D., Diamond S.L., Bates P. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl. Acad. Sci. USA. 2005;102:11876&#x2013;11881. doi: 10.1073/pnas.0505577102.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0505577102</ArticleId><ArticleId IdType="pmc">PMC1188015</ArticleId><ArticleId IdType="pubmed">16081529</ArticleId></ArticleIdList></Reference><Reference><Citation>Coutard B., Valle C., de Lamballerie X., Canard B., Seidah N.G., Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antivir. Res. 2020;176:104742. doi: 10.1016/j.antiviral.2020.104742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104742</ArticleId><ArticleId IdType="pmc">PMC7114094</ArticleId><ArticleId IdType="pubmed">32057769</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Chen W., Zhang Z., Deng Y., Lian J.Q., Du P., Wei D., Zhang Y., Sun X.X., Gong L., et al. CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells. Signal Transduct. Target. Ther. 2020;5:283. doi: 10.1038/s41392-020-00426-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00426-x</ArticleId><ArticleId IdType="pmc">PMC7714896</ArticleId><ArticleId IdType="pubmed">33277466</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xe9;ndez-Guerrero A., Laespada-Garc&#xed;a M.I., G&#xf3;mez-Grande A., Ruiz-Ortiz M., Blanco-Palmero V.A., Azcarate-Diaz F.J., R&#xe1;bano-Su&#xe1;rez P., &#xc1;lvarez-Torres E., de Fuenmayor-Fern&#xe1;ndez de la Hoz C.P., Vega P&#xe9;rez D., et al. Acute hypokinetic-rigid syndrome following SARS-CoV-2 infection. Neurology. 2020;95:e2109&#x2013;e2118. doi: 10.1212/WNL.0000000000010282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000010282</ArticleId><ArticleId IdType="pubmed">32641525</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen M.E., Eichel R., Steiner-Birmanns B., Janah A., Ioshpa M., Bar-Shalom R., Paul J.J., Gaber H., Skrahina V., Bornstein N.M., et al. A case of probable Parkinson&#x2019;s disease after SARS-CoV-2 infection. Lancet Neurol. 2020;19:804&#x2013;805. doi: 10.1016/S1474-4422(20)30305-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30305-7</ArticleId><ArticleId IdType="pmc">PMC7494295</ArticleId><ArticleId IdType="pubmed">32949534</ArticleId></ArticleIdList></Reference><Reference><Citation>Merello M., Bhatia K.P., Obeso J.A. SARS-CoV-2 and the risk of Parkinson&#x2019;s disease: Facts and fantasy. Lancet Neurol. 2021;20:94&#x2013;95. doi: 10.1016/S1474-4422(20)30442-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30442-7</ArticleId><ArticleId IdType="pmc">PMC7834123</ArticleId><ArticleId IdType="pubmed">33253627</ArticleId></ArticleIdList></Reference><Reference><Citation>Freidin M., Bennett M.V., Kessler J.A. Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta. Proc. Natl. Acad. Sci. USA. 1992;89:10440&#x2013;10443. doi: 10.1073/pnas.89.21.10440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.21.10440</ArticleId><ArticleId IdType="pmc">PMC50354</ArticleId><ArticleId IdType="pubmed">1279679</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartfai T., Schultzberg M. Cytokines in neuronal cell types. Neurochem. Int. 1993;22:435&#x2013;444. doi: 10.1016/0197-0186(93)90038-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-0186(93)90038-7</ArticleId><ArticleId IdType="pubmed">8485449</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto T., Yamashita A., Yamada K., Hata R.I. Immunohistochemical localization of chemokine CXCL14 in rat hypothalamic neurons. Neurosci. Lett. 2011;487:335&#x2013;340. doi: 10.1016/j.neulet.2010.10.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2010.10.051</ArticleId><ArticleId IdType="pubmed">20974226</ArticleId></ArticleIdList></Reference><Reference><Citation>Garay P.A., McAllister A.K. Novel roles for immune molecules in neural development: Implications for neurodevelopmental disorders. Front. Synaptic Neurosci. 2010;2:136. doi: 10.3389/fnsyn.2010.00136.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnsyn.2010.00136</ArticleId><ArticleId IdType="pmc">PMC3059681</ArticleId><ArticleId IdType="pubmed">21423522</ArticleId></ArticleIdList></Reference><Reference><Citation>Yirmiya R., Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav. Immun. 2011;25:181&#x2013;213. doi: 10.1016/j.bbi.2010.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2010.10.015</ArticleId><ArticleId IdType="pubmed">20970492</ArticleId></ArticleIdList></Reference><Reference><Citation>Fajgenbaum D.C., June C.H. Cytokine storm. N. Engl. J. Med. 2020;383:2255&#x2013;2273. doi: 10.1056/NEJMra2026131.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra2026131</ArticleId><ArticleId IdType="pmc">PMC7727315</ArticleId><ArticleId IdType="pubmed">33264547</ArticleId></ArticleIdList></Reference><Reference><Citation>Normandin E., Holroyd K.B., Collens S.I., Shaw B.M., Siddle K.J., Adams G., Rudy M., Solomon I.H., Anahtar M.N., Lemieux J.E., et al. Intrathecal inflammatory responses in the absence of SARS-CoV-2 nucleic acid in the CNS of COVID-19 hospitalized patients. J. Neurol. Sci. 2021;430:120023. doi: 10.1016/j.jns.2021.120023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2021.120023</ArticleId><ArticleId IdType="pmc">PMC8489278</ArticleId><ArticleId IdType="pubmed">34678659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilotto A., Masciocchi S., Volonghi I., De Giuli V., Caprioli F., Mariotto S., Ferrari S., Bozzetti S., Imarisio A., Risi B., et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) encephalitis is a cytokine release syndrome: Evidences from cerebrospinal fluid analysis. Clin. Infest. Dis. 2021;73:e3019&#x2013;e3026. doi: 10.1093/cid/ciaa1933.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1933</ArticleId><ArticleId IdType="pmc">PMC7799260</ArticleId><ArticleId IdType="pubmed">33395482</ArticleId></ArticleIdList></Reference><Reference><Citation>Guasp M., Mu&#xf1;oz-S&#xe1;nchez G., Mart&#xed;nez-Hern&#xe1;ndez E., Santana D., Carbayo A., Naranjo L., Bolos U., Framil M., Saiz A., Balasa M., et al. CSF biomarkers in COVID-19 associated encephalopathy and encephalitis predict long-term outcome. Front. Immunol. 2022;13:1600. doi: 10.3389/fimmu.2022.866153.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.866153</ArticleId><ArticleId IdType="pmc">PMC9035899</ArticleId><ArticleId IdType="pubmed">35479062</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinman L. Inflammatory cytokines at the summits of pathological signal cascades in brain diseases. Sci. Signal. 2013;6:pe3. doi: 10.1126/scisignal.2003898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scisignal.2003898</ArticleId><ArticleId IdType="pubmed">23322904</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinouchi K., Brown G., Pasternak G., Donner D.B. Identification and characterization of receptors for tumor necrosis factor-alpha in the brain. Biochem. Biopharm. Res. Commun. 1991;181:1532&#x2013;1538. doi: 10.1016/0006-291X(91)92113-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(91)92113-X</ArticleId><ArticleId IdType="pubmed">1662500</ArticleId></ArticleIdList></Reference><Reference><Citation>Szelenyi J. Cytokines and the central nervous system. Brain Res. Bull. 2001;54:329&#x2013;338. doi: 10.1016/S0361-9230(01)00428-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0361-9230(01)00428-2</ArticleId><ArticleId IdType="pubmed">11306183</ArticleId></ArticleIdList></Reference><Reference><Citation>Ban E., Milon G., Prudhomme N., Fillion G., Haour F. Receptors for interleukin-1 (alpha and beta) in mouse brain: Mapping and neuronal localization in hippocampus. Neuroscience. 1991;43:21&#x2013;30. doi: 10.1016/0306-4522(91)90412-H.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0306-4522(91)90412-H</ArticleId><ArticleId IdType="pubmed">1833666</ArticleId></ArticleIdList></Reference><Reference><Citation>Takao T., Tracey D.E., Mitchell W.M., De Souza E.B. Interleukin-1 receptors in mouse brain: Characterization and neuronal localization. Endocrinology. 1990;127:3070&#x2013;3078. doi: 10.1210/endo-127-6-3070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1210/endo-127-6-3070</ArticleId><ArticleId IdType="pubmed">2147409</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider H., Pitossi F., Balschun D., Wagner A., del Rey A., Besedovsky H.O. A neuromodulatory role of interleukin-1beta in the hippocampus. Proc. Natl. Acad. Sci. USA. 1998;95:7778&#x2013;7783. doi: 10.1073/pnas.95.13.7778.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.13.7778</ArticleId><ArticleId IdType="pmc">PMC22755</ArticleId><ArticleId IdType="pubmed">9636227</ArticleId></ArticleIdList></Reference><Reference><Citation>Avital A., Goshen I., Kamsler A., Segal M., Iverfeldt K., Richter-Levin G., Yirmiya R. Impaired interleukin-1 signaling is associated with deficits in hippocampal memory processes and neural plasticity. Hippocampus. 2003;13:826&#x2013;834. doi: 10.1002/hipo.10135.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.10135</ArticleId><ArticleId IdType="pubmed">14620878</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid A.W., Lynch M.A., Herron C.E. The effects of IL-1 receptor antagonist on beta amyloid mediated depression of LTP in the rat CA1 in vivo. Hippocampus. 2009;19:670&#x2013;676. doi: 10.1002/hipo.20542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hipo.20542</ArticleId><ArticleId IdType="pubmed">19115392</ArticleId></ArticleIdList></Reference><Reference><Citation>Braida D., Sacerdote P., Panerai A.E., Bianchi M., Aloisi A.M., Iosu&#xe8; S., Sala M. Cognitive function in young and adult IL (interleukin)-6 deficient mice. Behav. Brain Res. 2004;153:423&#x2013;429. doi: 10.1016/j.bbr.2003.12.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbr.2003.12.018</ArticleId><ArticleId IdType="pubmed">15265638</ArticleId></ArticleIdList></Reference><Reference><Citation>Curran B., O&#x2019;Connor J. The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience. 2001;108:83&#x2013;90. doi: 10.1016/S0306-4522(01)00405-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0306-4522(01)00405-5</ArticleId><ArticleId IdType="pubmed">11738133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cumiskey D., Pickering M., O&#x2019;Connor J.J. Interleukin-18 mediated inhibition of LTP in the rat dentate gyrus is attenuated in the presence of nGluR antagonists. Neurosci. Lett. 2007;412:206&#x2013;210. doi: 10.1016/j.neulet.2006.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.11.007</ArticleId><ArticleId IdType="pubmed">17123727</ArticleId></ArticleIdList></Reference><Reference><Citation>Filiano A.J., Xu Y., Tustison N.J., Marsh R.L., Baker W., Smirnov I., Overall C.C., Gadani S.P., Turner S.D., Weng Z., et al. Unexpected role of interferon-&#x3b3; in regulating neuronal connectivity and social behavior. Nature. 2016;535:425&#x2013;429. doi: 10.1038/nature18626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature18626</ArticleId><ArticleId IdType="pmc">PMC4961620</ArticleId><ArticleId IdType="pubmed">27409813</ArticleId></ArticleIdList></Reference><Reference><Citation>Belarbi K., Jopson T., Tweedie D., Arellano C., Luo W., Greig N.H., Rosi S. TNF-&#x3b1; protein synthesis inhibitor restores neuronal function and reverses cognitive deficits induced by chronic neuroinflammation. J. Neuroinflamm. 2012;9:23. doi: 10.1186/1742-2094-9-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1742-2094-9-23</ArticleId><ArticleId IdType="pmc">PMC3298520</ArticleId><ArticleId IdType="pubmed">22277195</ArticleId></ArticleIdList></Reference><Reference><Citation>Albensi B.C., Mattson M.P. Evidence for the involvement of TNF and NF-kappaB in hippocampal synaptic plasticity. Synapse. 2000;35:151&#x2013;159. doi: 10.1002/(SICI)1098-2396(200002)35:2&lt;151::AID-SYN8&gt;3.0.CO;2-P.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1098-2396(200002)35:2&lt;151::AID-SYN8&gt;3.0.CO;2-P</ArticleId><ArticleId IdType="pubmed">10611641</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Itakura E., Nelson G.M., Sheng M., Laurent P., Fenk L.A., Butcher R.A., Hedge R.S., de Bono M. IL-17 is a neuromodulator of Caernorhabditis elegans sensory responses. Nature. 2017;542:43&#x2013;48. doi: 10.1038/nature20818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature20818</ArticleId><ArticleId IdType="pmc">PMC5503128</ArticleId><ArticleId IdType="pubmed">28099418</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Filippo M., Mancini A., Bellingacci L., Gaetani L., Mazzocchetti P., Zelante T., La Barbera L., De Luca A., Tantucci M., Tozzi A., et al. Interleukin-17 affects synaptic plasticity and cognition in an experimental model of multiple sclerosis. Cell Rep. 2021;37:110094. doi: 10.1016/j.celrep.2021.110094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110094</ArticleId><ArticleId IdType="pubmed">34879272</ArticleId></ArticleIdList></Reference><Reference><Citation>Centonze D., Muzio L., Rossi S., Cavasinni F., De Chiara V., Bergami A., Musella A., D&#x2019;Amelio M., Cavallucci V., Martorana A., et al. Inflammation triggers synaptic alteration and degeneration in experimental autoimmune encephalomyelitis. J. Neurosci. 2009;29:3442&#x2013;3452. doi: 10.1523/JNEUROSCI.5804-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5804-08.2009</ArticleId><ArticleId IdType="pmc">PMC6665268</ArticleId><ArticleId IdType="pubmed">19295150</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandolesi G., Grasselli G., Musella A., Gentile A., Musumeci G., Sepman H., Haji N., Fresegna D., Bernardi G., Centonze D. GABAergic signaling and connectivity on Purkinje cells are impaired in experimental autoimmune encephalomyelitis. Neurobiol. Dis. 2012;46:414&#x2013;424. doi: 10.1016/j.nbd.2012.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2012.02.005</ArticleId><ArticleId IdType="pubmed">22349452</ArticleId></ArticleIdList></Reference><Reference><Citation>Haji N., Mandolesi G., Gentile A., Sacchetti L., Fresegna D., Rossi S., Musella A., Sepman H., Motta C., Studer V., et al. TNF-&#x3b1;-mediated anxiety in a mouse model of multiple sclerosis. Exp. Neurol. 2012;237:296&#x2013;303. doi: 10.1016/j.expneurol.2012.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2012.07.010</ArticleId><ArticleId IdType="pubmed">22836148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandolesi G., Musella A., Gentile A., Grasselli G., Haji N., Sepman H., Fresegna D., Bullitta S., De Vito F., Musumeci G., et al. Interleukin-1&#x3b2; alters glutamate transmission at purkinje cell synapses in a mouse model of multiple sclerosis. J. Neurosci. 2013;33:12105&#x2013;12121. doi: 10.1523/JNEUROSCI.5369-12.2013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5369-12.2013</ArticleId><ArticleId IdType="pmc">PMC6794065</ArticleId><ArticleId IdType="pubmed">23864696</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Filippo M., Tozzi A., Arcangeli S., de Iure A., Durante V., Di Gregorio M., Gardoni F., Calabresi P. Interferon-&#x3b2;1a modulates glutamate neurotransmission in the CNS through CaMKII and GluN2A-containing NMDA receptors. Neuropharmacology. 2016;100:98&#x2013;105. doi: 10.1016/j.neuropharm.2015.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2015.06.009</ArticleId><ArticleId IdType="pubmed">26116817</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S., Furlan R., De Chiara V., Motta C., Studer V., Mori F., Musella A., Bergami A., Muzio L., Bernardi G., et al. Interleukin-1&#x3b2; causes synaptic hyperexcitability in multiple sclerosis. Ann. Neurol. 2012;71:76&#x2013;83. doi: 10.1002/ana.22512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.22512</ArticleId><ArticleId IdType="pubmed">22275254</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi S., Studer V., Motta C., De Chiara V., Barbieri F., Bernardi G., Centonze D. Inflammation inhibits GABA transmission in multiple sclerosis. Mult. Scler. 2012;18:1633&#x2013;1635. doi: 10.1177/1352458512440207.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1352458512440207</ArticleId><ArticleId IdType="pubmed">22419673</ArticleId></ArticleIdList></Reference><Reference><Citation>Zalcman S., Green-Johnson J.M., Murray L., Nance D.M., Dyck D., Anisman H., Greenberg A.H. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994;643:40&#x2013;49. doi: 10.1016/0006-8993(94)90006-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(94)90006-X</ArticleId><ArticleId IdType="pubmed">7518332</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohankumar P.S., Thyagarajan S., Quadri S.K. Interleukin-1 stimulates the release of dopamine and dihydroxylphenylacetic acid from the hypothalamus in vivo. Life Sci. 1991;48:925&#x2013;930. doi: 10.1016/0024-3205(91)90040-I.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0024-3205(91)90040-I</ArticleId><ArticleId IdType="pubmed">1997793</ArticleId></ArticleIdList></Reference><Reference><Citation>Shintani F., Kanba S., Nakaki T., Nibuya M., Kinoshita N., Suzuki E., Yagi G., Kato R., Asai M. Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J. Neurosci. 1993;13:3574&#x2013;3581. doi: 10.1523/JNEUROSCI.13-08-03574.1993.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.13-08-03574.1993</ArticleId><ArticleId IdType="pmc">PMC6576546</ArticleId><ArticleId IdType="pubmed">8393485</ArticleId></ArticleIdList></Reference><Reference><Citation>Merali Z., Lacosta S., Anisman H. Effects of interleukin-1beta and mild stress on alterations of norepinephrine, dopamine and serotonin neurotransmission: A regional microdialysis study. Brain Res. 1997;761:225&#x2013;235. doi: 10.1016/S0006-8993(97)00312-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(97)00312-0</ArticleId><ArticleId IdType="pubmed">9252020</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile A., Fresegna D., Federici M., Musella A., Rizzo F.R., Sepman H., Bullitta S., De Vito F., Haji N., Rossi S., et al. Dopaminergic dysfunction is associated with IL-1b-dependent mood alterations in experimental autoimmune encephalomyelitis. Neurobiol. Dis. 2015;74:347&#x2013;358. doi: 10.1016/j.nbd.2014.11.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2014.11.022</ArticleId><ArticleId IdType="pubmed">25511803</ArticleId></ArticleIdList></Reference><Reference><Citation>Alonso R., Chaudieu I., Diorio J., Krishnamurthy A., Quirion R., Boksa P. Interleukin-2 modulates evoked release of [3H] dopamine in rat cultured mesencephalic cells. J. Neurochem. 1993;61:1284&#x2013;1290. doi: 10.1111/j.1471-4159.1993.tb13620.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.1993.tb13620.x</ArticleId><ArticleId IdType="pubmed">8376986</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapchak P.A. A role for interleukin-2 in the regulation of striatal dopaminergic function. Neuroreport. 1992;3:165&#x2013;168. doi: 10.1097/00001756-199202000-00011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00001756-199202000-00011</ArticleId><ArticleId IdType="pubmed">1623167</ArticleId></ArticleIdList></Reference><Reference><Citation>Anisman H., Kokkinidis L., Merali Z. Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Res. 1996;731:1&#x2013;11. doi: 10.1016/0006-8993(96)00460-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(96)00460-X</ArticleId><ArticleId IdType="pubmed">8883848</ArticleId></ArticleIdList></Reference><Reference><Citation>Petitto J.M., McCarthy D.B., Rinker C.M., Huang Z., Getty T. Modulation of behavioral and neurochemical measures of forebrain dopamine function in mice by species-specific interleukin-2. J. Neuroimmunol. 1997;73:183&#x2013;190. doi: 10.1016/S0165-5728(96)00196-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-5728(96)00196-8</ArticleId><ArticleId IdType="pubmed">9058775</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuto H., Kataoka Y., Horikawa T., Fujihara N., Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997;747:348&#x2013;351. doi: 10.1016/S0006-8993(96)01371-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(96)01371-6</ArticleId><ArticleId IdType="pubmed">9046014</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Alagbe O., Hu F., Mook D., Freeman A.A., Sanchez M.M., Kalin N.H., Ratti E., Nemeroff C.B., Miller A.H. Effects of interferon-alpha on rhesus monkeys: A nonhuman primate model of cytokine-induced depression. Biol. Psychiatry. 2007;62:1324&#x2013;1333. doi: 10.1016/j.biopsych.2007.05.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2007.05.026</ArticleId><ArticleId IdType="pmc">PMC2149847</ArticleId><ArticleId IdType="pubmed">17678633</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Miller A.H. Cytokine effects on the basal ganglia and dopamine function: The subcortical source of inflammatory malaise. Front. Neuroendocrinol. 2012;33:315&#x2013;327. doi: 10.1016/j.yfrne.2012.09.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yfrne.2012.09.003</ArticleId><ArticleId IdType="pmc">PMC3484236</ArticleId><ArticleId IdType="pubmed">23000204</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Mun J., Kimmel H.L., Nye J.A., Drake D.F., Hernandez C.R., Freeman A.A., Rye D.B., Goodman M.M., Howell L.L., et al. Chronic interferon-a decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology. 2013;38:2179&#x2013;2187. doi: 10.1038/npp.2013.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2013.115</ArticleId><ArticleId IdType="pmc">PMC3773667</ArticleId><ArticleId IdType="pubmed">23657438</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Hernandez C.R., Miller A.H. Levodopa reverses cytokine-induced reductions in striatal dopamine release. Int. J. Neuropsychopharmacol. 2015;18:pyu084. doi: 10.1093/ijnp/pyu084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ijnp/pyu084</ArticleId><ArticleId IdType="pmc">PMC4360218</ArticleId><ArticleId IdType="pubmed">25638816</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumai T., Tateischi T., Tanaka M., Watanable M., Shimizu H., Kobayashi S. Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci. 2000;67:663&#x2013;669. doi: 10.1016/S0024-3205(00)00660-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0024-3205(00)00660-3</ArticleId><ArticleId IdType="pubmed">12659172</ArticleId></ArticleIdList></Reference><Reference><Citation>Skrzydelski D., Guyon A., Daug&#xe9; V., Rov&#xe8;re C., Apartis E., Kitabgi P., Nahon J.L., Rost&#xe8;ne W., M&#xe9;lik Parsadaniantz S. The chemokine stromal cell-derived factor-1/CXCL12 activates the nigrostriatal dopamine system. J. Neurochem. 2007;102:1175&#x2013;1183. doi: 10.1111/j.1471-4159.2007.04639.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04639.x</ArticleId><ArticleId IdType="pubmed">17509088</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyon A., Skrzydelsi D., Rov&#xe8;re C., Rost&#xe8;ne W., M&#xe9;lik Parsadaniantz S., Nahon J.L. Stromal cell-derived factor-1alpha modulation of the excitability of rat substantia nigra dopaminergic neurons: Presynaptic mechanisms. J. Neurochem. 2006;96:1540&#x2013;1550. doi: 10.1111/j.1471-4159.2006.03659.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.03659.x</ArticleId><ArticleId IdType="pubmed">16476083</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyon A., Skrzydelski D., Rov&#xe8;re C., Apartis E., Rost&#xe8;ne W., Kitabgi P., M&#xe9;lik Parsadaniantz S., Nahon J.L. Stromal-cell-derived factor 1alpha/CXCL12 modulates high-threshold calcium currents in rat substantia nigra. Eur. J. Neurosci. 2008;28:862&#x2013;870. doi: 10.1111/j.1460-9568.2008.06367.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1460-9568.2008.06367.x</ArticleId><ArticleId IdType="pubmed">18671738</ArticleId></ArticleIdList></Reference><Reference><Citation>Vumma R., Johansson J., Venizelos N. Proinflammatory cytokines and oxidative stress decrease the transport of dopamine precursor tyrosine in human fibroblasts. Neuropsychobiology. 2017;75:178&#x2013;184. doi: 10.1159/000485130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000485130</ArticleId><ArticleId IdType="pubmed">29339668</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitagami T., Yamada K., Miura H., Hashimoto R., Nabeshima T., Ohta T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: Role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res. 2003;978:104&#x2013;114. doi: 10.1016/S0006-8993(03)02776-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(03)02776-8</ArticleId><ArticleId IdType="pubmed">12834904</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Treadway M.T. Inflammation effects on motivation and motor activity: Role of dopamine. Neuropsychopharmacology. 2017;42:216&#x2013;241. doi: 10.1038/npp.2016.143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2016.143</ArticleId><ArticleId IdType="pmc">PMC5143486</ArticleId><ArticleId IdType="pubmed">27480574</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W., Knowlton D., Woodward W.R., Habecker B.A. Regulation of noradrenergic function by inflammatory cytokines and depolarization. J. Neurochem. 2003;86:774&#x2013;783. doi: 10.1046/j.1471-4159.2003.01890.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2003.01890.x</ArticleId><ArticleId IdType="pubmed">12859689</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Li L., Marvan P.J., Woolwine B.J., Harrison D.G., Raison C.L., Miller A.H. Tyrosine metabolism during interferon-alpha administration: Association with fatigue and CSF dopamine concentrations. Brain Behav. Immun. 2013;31:153&#x2013;160. doi: 10.1016/j.bbi.2012.10.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2012.10.010</ArticleId><ArticleId IdType="pmc">PMC3578984</ArticleId><ArticleId IdType="pubmed">23072726</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoller H., Schloegl A., Schroecksnadel S., Wolfgang V., Fuchs D. Interferon-alpha therapy in patients with hepatitis C virus infection increases plasma phenylalanine and the phenylalanine to tyrosine ratio. J. Interferon Cytokine Res. 2012;32:216&#x2013;220. doi: 10.1089/jir.2011.0093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.2011.0093</ArticleId><ArticleId IdType="pubmed">22191466</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazumori H., Ishihara S., Rumi M.A., Ortega-Cava C.F., Kadowaki Y., Kinoshita Y. Transforming growth factor-alpha directly augments histidine decarboxylase and vesicular monoamine transporter 2 production in rat enterochromaffin-like cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2004;286:G508&#x2013;G514. doi: 10.1152/ajpgi.00269.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpgi.00269.2003</ArticleId><ArticleId IdType="pubmed">14563668</ArticleId></ArticleIdList></Reference><Reference><Citation>Mor&#xf3;n J.A., Zakharova I., Ferrer J.V., Merrill G.A., Hope B., Lafer E.M., Lin Z.C., Wang J.B., Javitch J.A., Galli A., et al. Mitogen-activated protein kinase regulates dopamine transporter surface expression and dopamine transporter capacity. J. Neurosci. 2003;23:8480&#x2013;8488. doi: 10.1523/JNEUROSCI.23-24-08480.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-24-08480.2003</ArticleId><ArticleId IdType="pmc">PMC6740378</ArticleId><ArticleId IdType="pubmed">13679416</ArticleId></ArticleIdList></Reference><Reference><Citation>Crunfli F., Carregari V.C., Veras F.P., Silva L.S., Nogueira M.H., Antunes A.S.L.M., Vendramini P.H., Valen&#xe7;a A.G.F., Brand&#xe3;o-Teles C., da Silva Zuccoli G., et al. Morphological, cellular, and molecular basis of brain infection in COVID-19 patients. Proc. Natl. Acad. Sci. USA. 2022;119:e2200960119. doi: 10.1073/pnas.2200960119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2200960119</ArticleId><ArticleId IdType="pmc">PMC9436354</ArticleId><ArticleId IdType="pubmed">35951647</ArticleId></ArticleIdList></Reference><Reference><Citation>Asanuma M., Miyazaki I., Murakami S., Diaz-Corrales F.J., Ogawa N. Striatal astrocytes act as a reservoir for L-DOPA. PLoS ONE. 2014;9:e106362. doi: 10.1371/journal.pone.0106362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0106362</ArticleId><ArticleId IdType="pmc">PMC4154692</ArticleId><ArticleId IdType="pubmed">25188235</ArticleId></ArticleIdList></Reference><Reference><Citation>Adermark L., Lagstr&#xf6;m O., Loft&#xe9;n A., Licheri V., Haven&#xe4;ng A., Loi E.A., Stomberg R., S&#xf6;derpalm B., Domi A., Ericson M. Astrocytes modulate extracellular neurotransmitter levels and excitatory neurotransmission in dorsolateral striatum via dopamine D2 receptor signaling. Neuropsychopharmacology. 2022;47:1493&#x2013;1502. doi: 10.1038/s41386-021-01232-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41386-021-01232-x</ArticleId><ArticleId IdType="pmc">PMC9206030</ArticleId><ArticleId IdType="pubmed">34811469</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwarcz R., Stone T.W. The kynurenine pathway and the brain: Challenges, controversies and promises. Neuropharmacology. 2017;112:237&#x2013;247. doi: 10.1016/j.neuropharm.2016.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuropharm.2016.08.003</ArticleId><ArticleId IdType="pmc">PMC5803785</ArticleId><ArticleId IdType="pubmed">27511838</ArticleId></ArticleIdList></Reference><Reference><Citation>Rassoulpour A., Wu H.Q., Ferre S., Schwarcz R. Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 2005;93:762&#x2013;765. doi: 10.1111/j.1471-4159.2005.03134.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03134.x</ArticleId><ArticleId IdType="pubmed">15836634</ArticleId></ArticleIdList></Reference><Reference><Citation>Amori L., Wu H.Q., Marinozzi M., Pellicciari R., Guidetti P., Schwarcz R. Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience. 2009;159:196&#x2013;203. doi: 10.1016/j.neuroscience.2008.11.055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.11.055</ArticleId><ArticleId IdType="pmc">PMC3073137</ArticleId><ArticleId IdType="pubmed">19138730</ArticleId></ArticleIdList></Reference><Reference><Citation>Carpenedo R., Pittaluga A., Cozzi A., Attucci S., Galli A., Raiteri M., Moroni F. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. Eur. J. Neurosci. 2001;13:2141&#x2013;2147. doi: 10.1046/j.0953-816x.2001.01592.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.0953-816x.2001.01592.x</ArticleId><ArticleId IdType="pubmed">11422455</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice M.E., Patel J.C., Cragg S.J. Dopamine release in the basal ganglia. Neuroscience. 2011;198:112&#x2013;137. doi: 10.1016/j.neuroscience.2011.08.066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.08.066</ArticleId><ArticleId IdType="pmc">PMC3357127</ArticleId><ArticleId IdType="pubmed">21939738</ArticleId></ArticleIdList></Reference><Reference><Citation>Avshalumov M.V., Chen B.T., Marshall S.P., Pe&#xf1;a D.M., Rice M.E. Glutamate-dependent inhibition of dopamine release in striatum is mediated by a new diffusible messenger, H2O2. J. Neurosci. 2003;23:2744&#x2013;2750. doi: 10.1523/JNEUROSCI.23-07-02744.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.23-07-02744.2003</ArticleId><ArticleId IdType="pmc">PMC6742066</ArticleId><ArticleId IdType="pubmed">12684460</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard V., Bolam J.P. Subcellular and subsynaptic distribution of the NR1 subunit of the NMDA receptor in the neostriatum and globus pallidus of the rat: Co-localization at synapses with the GluR2/3 subunit of the AMPA receptor. Eur. J. Neurosci. 1998;10:3721&#x2013;3736. doi: 10.1046/j.1460-9568.1998.00380.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1460-9568.1998.00380.x</ArticleId><ArticleId IdType="pubmed">9875351</ArticleId></ArticleIdList></Reference><Reference><Citation>Avshalumov M.V., Rice M.E. Activation of ATP-sensitive K+ (K(ATP)) channels by H2O2 underlies glutamate-dependent inhibition of striatal dopamine release. Proc. Natl. Acad. Sci. USA. 2003;100:11729&#x2013;11734. doi: 10.1073/pnas.1834314100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1834314100</ArticleId><ArticleId IdType="pmc">PMC208826</ArticleId><ArticleId IdType="pubmed">13679582</ArticleId></ArticleIdList></Reference><Reference><Citation>Avshalumov M.V., Patel J.C., Rice M.E. AMPA receptor-dependent H2O2 generation in striatal medium spiny neurons but not dopamine axons: One source of a retrograde signal that can inhibit dopamine release. J. Neurophysiol. 2008;100:1590&#x2013;1601. doi: 10.1152/jn.90548.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/jn.90548.2008</ArticleId><ArticleId IdType="pmc">PMC2544473</ArticleId><ArticleId IdType="pubmed">18632893</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu K.E., Fazal F.M., Parker K.R., Zou J., Chang H.Y. RNA-GPS predicts SARS-CoV-2 RNA residency to host mitochondria and nucleolus. Cell Syst. 2020;11:102&#x2013;108.e3. doi: 10.1016/j.cels.2020.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2020.06.008</ArticleId><ArticleId IdType="pmc">PMC7305881</ArticleId><ArticleId IdType="pubmed">32673562</ArticleId></ArticleIdList></Reference><Reference><Citation>Mander P.K., Jekabsone A., Brown G.C. Microglia proliferation is regulated by hydrogen peroxide from NADPH oxidase. J. Immunol. 2006;176:1046&#x2013;1052. doi: 10.4049/jimmunol.176.2.1046.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.2.1046</ArticleId><ArticleId IdType="pubmed">16393992</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha R.N., Pahan K. Regulation of inducible nitric oxide synthase gene in glial cells. Antioxid. Redox Signal. 2006;8:929&#x2013;947. doi: 10.1089/ars.2006.8.929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2006.8.929</ArticleId><ArticleId IdType="pmc">PMC1963415</ArticleId><ArticleId IdType="pubmed">16771683</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartung H., Threlfell S., Cragg S.J. Nitric oxide donors enhance the frequency dependence of dopamine release in nucleus accumbens. Neuropsychopharmacology. 2011;36:1811&#x2013;1822. doi: 10.1038/npp.2011.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/npp.2011.62</ArticleId><ArticleId IdType="pmc">PMC3154099</ArticleId><ArticleId IdType="pubmed">21508928</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss J.P., Hennings E.C., Zsilla G., Vizi E.S. A possible role of nitric oxide in the regulation of dopamine transporter function in the striatum. Neurochem. Int. 1999;34:345&#x2013;450. doi: 10.1016/s0197-0186(99)00019-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0197-0186(99)00019-4</ArticleId><ArticleId IdType="pubmed">10372921</ArticleId></ArticleIdList></Reference><Reference><Citation>Ara J., Przedborski S., Naini A.B., Jackson-Lewis V., Trilifetti R.R., Horwitz J., Ischiropoulos H. Inactivation of tyrosine hydroxylase by nitration following exposure to peroxynitrite and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Proc. Natl. Acad. Sci. USA. 1998;95:7659&#x2013;7663. doi: 10.1073/pnas.95.13.7659.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.95.13.7659</ArticleId><ArticleId IdType="pmc">PMC22714</ArticleId><ArticleId IdType="pubmed">9636206</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y.F., Raab-Graham K., Jan Y.N., Jan L.Y. NO stimulation of ATP-sensitive potassium channels: Involvement of Ras/mitogen-activated protein kinase pathway and contribution to neuroprotection. Proc. Natl. Acad. Sci. USA. 2004;101:7799&#x2013;7804. doi: 10.1073/pnas.0402496101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0402496101</ArticleId><ArticleId IdType="pmc">PMC419686</ArticleId><ArticleId IdType="pubmed">15136749</ArticleId></ArticleIdList></Reference><Reference><Citation>Aviner R., Frydman J. Proteostasis in viral infection: Unfolding the complex virus-chaperone interplay. Cold Spring Harb. Perspect. Biol. 2020;12:a034090. doi: 10.1101/cshperspect.a034090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/cshperspect.a034090</ArticleId><ArticleId IdType="pmc">PMC7050591</ArticleId><ArticleId IdType="pubmed">30858229</ArticleId></ArticleIdList></Reference><Reference><Citation>Balchin D., Hayer-Hartl M., Hartl F.U. In vivo aspects of protein folding and quality control. Science. 2016;353:aac4354. doi: 10.1126/science.aac4354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aac4354</ArticleId><ArticleId IdType="pubmed">27365453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D., Klann K., Kock B., Widera M., Krause D., Ciesek S., Cinatl J., M&#xfc;nch C. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets. Nature. 2020;583:469&#x2013;472. doi: 10.1038/s41586-020-2332-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2332-7</ArticleId><ArticleId IdType="pubmed">32408336</ArticleId></ArticleIdList></Reference><Reference><Citation>Marateaux L., Campanelli J.T., Scheller R.H. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1988;8:2804&#x2013;2815. doi: 10.1523/JNEUROSCI.08-08-02804.1988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.08-08-02804.1988</ArticleId><ArticleId IdType="pmc">PMC6569395</ArticleId><ArticleId IdType="pubmed">3411354</ArticleId></ArticleIdList></Reference><Reference><Citation>George J.M. The synuccleins. Genome Biol. 2002;3:reviews3002.1. doi: 10.1186/gb-2001-3-1-reviews3002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/gb-2001-3-1-reviews3002</ArticleId><ArticleId IdType="pmc">PMC150459</ArticleId><ArticleId IdType="pubmed">11806835</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez R.G., Waymire J.C., Lin E., Liu J.J., Guo F., Zigmond M.J. A role for alpha-synuclein in the regulation of dopamine biosynthesis. J. Neurosci. 2002;22:3090&#x2013;3099. doi: 10.1523/JNEUROSCI.22-08-03090.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-08-03090.2002</ArticleId><ArticleId IdType="pmc">PMC6757524</ArticleId><ArticleId IdType="pubmed">11943812</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D., Jin L., Wang H., Zhao H., Zhao C., Duan C., Lu L., Wu B., Yu S., Chan P., et al. Silencing alpha-synuclein gene expression enhances tyrosine hydroxylase activity in MN9D cells. Neurochem. Res. 2008;33:1401&#x2013;1409. doi: 10.1007/s11064-008-9599-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-008-9599-7</ArticleId><ArticleId IdType="pmc">PMC2413118</ArticleId><ArticleId IdType="pubmed">18357527</ArticleId></ArticleIdList></Reference><Reference><Citation>Tehranian R., Montoya S.E., Van Laar A.D., Hastings T.G., Perez R.G. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J. Neurochem. 2006;99:1188&#x2013;1196. doi: 10.1111/j.1471-4159.2006.04146.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04146.x</ArticleId><ArticleId IdType="pubmed">16981894</ArticleId></ArticleIdList></Reference><Reference><Citation>Somayaji M., Cataldi S., Choi S.J., Edwards R.H., Mosharov E.V., Sulzer D. A dual role for &#x3b1;-synuclein in facilitation and depression of dopamine release from substantia nigra neurons in vivo. Proc. Natl. Acad. Sci. USA. 2020;117:32701&#x2013;32710. doi: 10.1073/pnas.2013652117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2013652117</ArticleId><ArticleId IdType="pmc">PMC7768743</ArticleId><ArticleId IdType="pubmed">33273122</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavich L., Tanila H., Veps&#xe4;l&#xe4;inen S., J&#xe4;k&#xe4;l&#xe4; P. Role of alpha-synuclein in presynaptic dopamine recruitment. J. Neurosci. 2004;24:11165&#x2013;11170. doi: 10.1523/JNEUROSCI.2559-04.2004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2559-04.2004</ArticleId><ArticleId IdType="pmc">PMC6730279</ArticleId><ArticleId IdType="pubmed">15590933</ArticleId></ArticleIdList></Reference><Reference><Citation>Fountaine T.M., Wade-Martins R. RNA interference-mediated knockdown of alpha-synuclein protects human dopaminergic neuroblastoma cells from MPP(+) toxicity and reduces dopamine transport. J. Neurosci. Res. 2007;85:351&#x2013;363. doi: 10.1002/jnr.21125.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21125</ArticleId><ArticleId IdType="pubmed">17131421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wersinger C., Sidhu A. Attenuation of dopamine transporter activity by alpha-synuclein. Neurosci. Lett. 2003;340:189&#x2013;192. doi: 10.1016/S0304-3940(03)00097-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(03)00097-1</ArticleId><ArticleId IdType="pubmed">12672538</ArticleId></ArticleIdList></Reference><Reference><Citation>Venda L.L., Cragg S.J., Buchman V.L., Wade-Martins R. &#x3b1;-Synuclein and dopamine at the crossroads of Parkinson&#x2019;s disease. Trends Neurosci. 2010;33:559&#x2013;568. doi: 10.1016/j.tins.2010.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2010.09.004</ArticleId><ArticleId IdType="pmc">PMC3631137</ArticleId><ArticleId IdType="pubmed">20961626</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao N., Li Y.H., Li X., Yu S., Fu G.L., Chen B. Effect of alpha-synuclein on the promoter activity of tyrosine hydroxylase gene. Neurosci. Bull. 2007;23:53&#x2013;57. doi: 10.1007/s12264-007-0008-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-007-0008-z</ArticleId><ArticleId IdType="pmc">PMC5550569</ArticleId><ArticleId IdType="pubmed">17592526</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng X., Tehranian R., Dietrich P., Stefanis L., Perez R.G. Alpha-synuclein activation of protein phosphatase 2A reduces tyrosine hydroxylase phosphorylation in dopaminergic cells. J. Cell Sci. 2005;118:3523&#x2013;3530. doi: 10.1242/jcs.02481.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.02481</ArticleId><ArticleId IdType="pubmed">16030137</ArticleId></ArticleIdList></Reference><Reference><Citation>Masliah E., Rockenstein E., Veinbergs I., Mallory M., Hashimoto M., Takeda A., Sagara Y., Sisk A., Mucke L. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science. 2000;287:1265&#x2013;1269. doi: 10.1126/science.287.5456.1265.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.287.5456.1265</ArticleId><ArticleId IdType="pubmed">10678833</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirik D., Rosenblad C., Burger C., Lundberg C., Johansen T.E., Muzyczka N., Mandel R.J., Bj&#xf6;rklund A. Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of &#x3b1;-Synuclein in the Nigrostriatal System. J. Neurosci. 2002;22:2780&#x2013;2791. doi: 10.1523/JNEUROSCI.22-07-02780.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.22-07-02780.2002</ArticleId><ArticleId IdType="pmc">PMC6758323</ArticleId><ArticleId IdType="pubmed">11923443</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavich L., Oksman M., Tanila H., Kerokoski P., Hiltunen M., van Groen T., Puoliv&#xe4;li J., M&#xe4;nnist&#xf6; P.T., Garc&#xed;a-Horsman A., MacDonald E., et al. Locomotor activity and evoked dopamine release are reduced in mice overexpressing A30P-mutated human alpha-synuclein. Neurobiol. Dis. 2005;20:303&#x2013;313. doi: 10.1016/j.nbd.2005.03.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2005.03.010</ArticleId><ArticleId IdType="pubmed">16242637</ArticleId></ArticleIdList></Reference><Reference><Citation>Larsen K.E., Schmitz Y., Troyen M.D., Mosharov E., Dietrich P., Quazi A.Z., Savalle M., Nemani V., Chaudhry F.A., Edwards R.H., et al. Alpha-synuclein overexpression in PC12 and chromaffin cells impairs catecholamine release by interfering with a late step in exocytosis. J. Neurosci. 2006;26:11915&#x2013;11922. doi: 10.1523/JNEUROSCI.3821-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3821-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674868</ArticleId><ArticleId IdType="pubmed">17108165</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemani V.M., Lu W., Berge V., Nakamura K., Onoa B., Lee M.K., Chaudhry F.A., Nicoll R.A., Edwards R.H. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron. 2010;65:66&#x2013;79. doi: 10.1016/j.neuron.2009.12.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2009.12.023</ArticleId><ArticleId IdType="pmc">PMC3119527</ArticleId><ArticleId IdType="pubmed">20152114</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler A.D., Bevis B.J., Shorter J., Strathearn K.E., Hamamichi S., Su L.J., Caldwell K.A., Caldwell G.A., Rochet J.C., McCaffery J.M., et al. The Parkinson&#x2019;s disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc. Natl. Acad. Sci. USA. 2008;105:145&#x2013;150. doi: 10.1073/pnas.0710685105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0710685105</ArticleId><ArticleId IdType="pmc">PMC2224176</ArticleId><ArticleId IdType="pubmed">18162536</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbut D., Stolzenberg E., Zasloff M. Gastrointestinal immunity and alpha-synuclein. J. Parkinson Dis. 2019;9:S313&#x2013;S322. doi: 10.3233/JPD-191702.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-191702</ArticleId><ArticleId IdType="pmc">PMC6839499</ArticleId><ArticleId IdType="pubmed">31594249</ArticleId></ArticleIdList></Reference><Reference><Citation>Greten-Harrison B., Polydoro M., Morimoto-Tomita M., Diao L., Williams A.M., Nie E.H., Makani S., Tian N., Castillo P.E., Buchman V.L., et al. &#x3b1;&#x3b2;&#x3b3;-synuclein triple knockout mice reveal age-dependent neuronal dysfunction. Proc. Natl. Acad. Sci. USA. 2010;107:19573&#x2013;19578. doi: 10.1073/pnas.1005005107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1005005107</ArticleId><ArticleId IdType="pmc">PMC2984188</ArticleId><ArticleId IdType="pubmed">20974939</ArticleId></ArticleIdList></Reference><Reference><Citation>Beatman E.L., Massey A., Shives K.D., Burrack K.S., Chamanian M., Morrison T.E., Beckham J.D. Alpha-synuclein expression restricts RNA viral infections in the brain. J. Virol. 2015;90:2767&#x2013;2782. doi: 10.1128/JVI.02949-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02949-15</ArticleId><ArticleId IdType="pmc">PMC4810656</ArticleId><ArticleId IdType="pubmed">26719256</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson J.J., Shutinoski B., Dong L., Meng F., Elleithy D., Lengacher N.A., Nguyen A.P., Cron G.O., Jiang Q., Roberson E.D., et al. Holocranohistochemistry enables the visualization of &#x3b1;-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. J. Neural Transm. 2017;124:721&#x2013;738. doi: 10.1007/s00702-017-1726-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-017-1726-7</ArticleId><ArticleId IdType="pmc">PMC5446848</ArticleId><ArticleId IdType="pubmed">28477284</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolzenberg E., Berry D., Yang D., Lee E.Y., Kroemer A., Kaufman S., Wong G.C.L., Oppenheim J.J., Sen S., Fishbein T., et al. A role for neuronal alpha-synuclein in gastrointestinal immunity. J. Innate Immun. 2017;9:456&#x2013;463. doi: 10.1159/000477990.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000477990</ArticleId><ArticleId IdType="pmc">PMC5865636</ArticleId><ArticleId IdType="pubmed">28651250</ArticleId></ArticleIdList></Reference><Reference><Citation>Alam M.M., Yang D., Li X.Q., Liu J., Back T.C., Trivett A., Karim B., Barbut D., Zasloff M., Oppenheim J.J. Alpha-synuclein, the culprit in Parkinson&#x2019;s disease, is required for normal immune function. Cell Rep. 2022;38:110090. doi: 10.1016/j.celrep.2021.110090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2021.110090</ArticleId><ArticleId IdType="pmc">PMC10258816</ArticleId><ArticleId IdType="pubmed">35021075</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanji K., Mori F., Imaizumi T., Yoshida H., Matsumiya T., Tamo W., Yoshimoto M., Odagiri H., Aasaki M., Takahashi H., et al. Upregulation of alpha-synuclein by lipopolysaccharide and interleukin-1 in human macrophages. Pathol. Int. 2002;52:572&#x2013;577. doi: 10.1046/j.1440-1827.2002.01385.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1827.2002.01385.x</ArticleId><ArticleId IdType="pubmed">12406186</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae E.J., Choi M., Kim J.T., Kim D.K., Jung M.K., Kim C., Kim T.K., Lee J.S., Jung B.C., Shin S.J., et al. TNF-&#x3b1; promotes &#x3b1;-synuclein propagation through stimulation of senescence-associated lysosomal exocytosis. Exp. Mol. Med. 2022;54:788&#x2013;800. doi: 10.1038/s12276-022-00789-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s12276-022-00789-x</ArticleId><ArticleId IdType="pmc">PMC9352737</ArticleId><ArticleId IdType="pubmed">35790884</ArticleId></ArticleIdList></Reference><Reference><Citation>Labrie V., Brundin P. Alpha-synuclein to the rescue: Immune cell recruitment by alpha-synuclein during gastrointestinal infection. J. Innate Immun. 2017;9:437&#x2013;440. doi: 10.1159/000479653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000479653</ArticleId><ArticleId IdType="pmc">PMC5607025</ArticleId><ArticleId IdType="pubmed">28866688</ArticleId></ArticleIdList></Reference><Reference><Citation>Shameli A., Xiao W., Zheng Y., Shyu S., Sumodi J., Meyerson H., Harding C.V., Maitta R.W. A critical role for alpha-synuclein in development and function of T lymphocytes. Immunobiology. 2016;221:333&#x2013;340. doi: 10.1016/j.imbio.2015.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2015.10.002</ArticleId><ArticleId IdType="pmc">PMC4688145</ArticleId><ArticleId IdType="pubmed">26517968</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasen A., Houck C., Burmeister A.R., Sha Q., Brundin L., Brundin P. Upregulation of &#x3b1;-synuclein following immune activation: Possible trigger of Parkinson&#x2019;s disease. Neurobiol. Dis. 2022;166:105654. doi: 10.1016/j.nbd.2022.105654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105654</ArticleId><ArticleId IdType="pubmed">35143968</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheiblich H., Bousset L., Schwartz S., Griep A., Latz E., Melki R., Heneka M.T. Microglial NLRP3 inflammasome activation upon TLR2 and TLR5 ligation by distinct &#x3b1;-synuclein assemblies. J. Immunol. 2021;207:2143&#x2013;2154. doi: 10.4049/jimmunol.2100035.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2100035</ArticleId><ArticleId IdType="pmc">PMC8490941</ArticleId><ArticleId IdType="pubmed">34507948</ArticleId></ArticleIdList></Reference><Reference><Citation>Trudler D., Nazor K.L., Eisele Y.S., Grabauskas T., Dolatabadi N., Parker J., Sultan A., Zhong Z., Goodwin M.S., Levites Y., et al. Soluble &#x3b1;-synuclein-antibody complexes activate the NLRP3 inflammasome in hiPSC-derived microglia. Proc. Natl. Acad. Sci. USA. 2021;118:e2025847118. doi: 10.1073/pnas.2025847118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2025847118</ArticleId><ArticleId IdType="pmc">PMC8054017</ArticleId><ArticleId IdType="pubmed">33833060</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.J., Suk J.E., Bae E.J., Lee S.J. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 2008;372:423&#x2013;428. doi: 10.1016/j.bbrc.2008.05.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2008.05.045</ArticleId><ArticleId IdType="pubmed">18492487</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar S., Dammer E.B., Malovic E., Olsen A.L., Raza S.A., Gao T., Xiao H., Oliver D.L., Duong D., Joers V., et al. Molecular Signatures of Neuroinflammation Induced by &#x3b1;Synuclein Aggregates in Microglial Cells. Front. Immunol. 2020;11:33. doi: 10.3389/fimmu.2020.00033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00033</ArticleId><ArticleId IdType="pmc">PMC7006296</ArticleId><ArticleId IdType="pubmed">32082315</ArticleId></ArticleIdList></Reference><Reference><Citation>Semerdzhiev S.A., Fakhree M.A.A., Segers-Nolten I., Blum C., Claessens M.M.A.E. Interactions between SARS-CoV-2 N-protein and &#x3b1;-synclein accelerate amyloid formation. ACS Chem. Neurosci. 2022;13:143&#x2013;150. doi: 10.1021/acschemneuro.1c00666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.1c00666</ArticleId><ArticleId IdType="pmc">PMC8739828</ArticleId><ArticleId IdType="pubmed">34860005</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Zhang X., Huang Z., Ma K. SARS-CoV-2 proteins interact with alpha synuclein and induce Lewy body-like pathology in vitro. Int. J. Mol. Sci. 2022;23:3394. doi: 10.3390/ijms23063394.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23063394</ArticleId><ArticleId IdType="pmc">PMC8949667</ArticleId><ArticleId IdType="pubmed">35328814</ArticleId></ArticleIdList></Reference><Reference><Citation>Albornoz E.A., Amarilla A.A., Modhiran N., Parker S., Li X.X., Wijesundara D.K., Aguado J., Zamora A.P., McMillan C.L.D., Liang B., et al. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike protein. Mol. Psychiatry. 2022 doi: 10.1038/s41380-022-01831-0. ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-022-01831-0</ArticleId><ArticleId IdType="pmc">PMC10615762</ArticleId><ArticleId IdType="pubmed">36316366</ArticleId></ArticleIdList></Reference><Reference><Citation>Fellner L., Irschick R., Schanda K., Reindl M., Klimaschewski L., Poewe W., Wenning G.K., Stefanova N. Toll-like receptor 4 is required for a-synuclein dependent activation of microglia and astroglia. Glia. 2013;61:349&#x2013;360. doi: 10.1002/glia.22437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.22437</ArticleId><ArticleId IdType="pmc">PMC3568908</ArticleId><ArticleId IdType="pubmed">23108585</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Kuang M., Li J., Zhu L., Jia Z., Guo X., Hu Y., Kong J., Yin H., Wang X., et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 2021;31:818&#x2013;820. doi: 10.1038/s41422-021-00495-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00495-9</ArticleId><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388:839&#x2013;840. doi: 10.1038/42166.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/42166</ArticleId><ArticleId IdType="pubmed">9278044</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson D.W., Fujishiro H., Orr C., DelleDonne A., Josephs K.A., Frigerio R., Burnett M., Parisi J.E., Klos K.J., Ahlskog J.E. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat. Disord. 2009;15((Suppl. 3)):S1&#x2013;S5. doi: 10.1016/S1353-8020(09)70769-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(09)70769-2</ArticleId><ArticleId IdType="pubmed">20082965</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolters E.C. Non-motor extranigral signs and symptoms in Parkinson&#x2019;s disease. Parkinsonism Relat. Disord. 2009;15((Suppl. 3)):S6&#x2013;S12. doi: 10.1016/S1353-8020(09)70770-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1353-8020(09)70770-9</ArticleId><ArticleId IdType="pubmed">20083010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson&#x2019;s disease. Trends Neurosci. 2007;30:244&#x2013;250. doi: 10.1016/j.tins.2007.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tins.2007.03.009</ArticleId><ArticleId IdType="pubmed">17418429</ArticleId></ArticleIdList></Reference><Reference><Citation>Picconi B., Pisani A., Barone I., Bonsi P., Centonze D., Bernardi G., Calabresi P. Pathological synaptic plasticity in the striatum: Implications for Parkinson&#x2019;s disease. Neurotoxicology. 2005;26:779&#x2013;783. doi: 10.1016/j.neuro.2005.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuro.2005.02.002</ArticleId><ArticleId IdType="pubmed">15927256</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbriani P., Martella G., Bonsi P., Pisani A. Oxidative stress and synaptic dysfunction in rodent models of Parkinson&#x2019;s disease. Neurobiol. Dis. 2022;173:105851. doi: 10.1016/j.nbd.2022.105851.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2022.105851</ArticleId><ArticleId IdType="pubmed">36007757</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauwendraat C., Nalls M.A., Singleton A.B. The genetic architecture of Parkinson&#x2019;s disease. Lancet Neurol. 2020;19:170&#x2013;178. doi: 10.1016/S1474-4422(19)30287-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(19)30287-X</ArticleId><ArticleId IdType="pmc">PMC8972299</ArticleId><ArticleId IdType="pubmed">31521533</ArticleId></ArticleIdList></Reference><Reference><Citation>Kline E.M., Houser M.C., Herrick M.K., Seibler P., Klein C., West A., Tansey M.G. Genetic and environmental factors in Parkinson&#x2019;s disease converge on immune function and inflammation. Mov. Disord. 2021;36:25&#x2013;36. doi: 10.1002/mds.28411.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28411</ArticleId><ArticleId IdType="pmc">PMC8285924</ArticleId><ArticleId IdType="pubmed">33314312</ArticleId></ArticleIdList></Reference><Reference><Citation>Harms A.S., Ferreira S.A., Romero-Ramos M. Periphery and brain, innate and adaptive immunity in Parkinson&#x2019;s disease. Acta Neuropathol. 2021;141:527&#x2013;545. doi: 10.1007/s00401-021-02268-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-021-02268-5</ArticleId><ArticleId IdType="pmc">PMC7952334</ArticleId><ArticleId IdType="pubmed">33555429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsch E.C., Standaert D.G. Ten unsolved questions about neuroinflammation in Parkinson&#x2019;s disease. Mov. Disord. 2020;36:16&#x2013;24. doi: 10.1002/mds.28075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.28075</ArticleId><ArticleId IdType="pubmed">32357266</ArticleId></ArticleIdList></Reference><Reference><Citation>Smeyne R.J., Noyce A.J., Byrne M., Savica R., Marras C. Infection and risk of Parkinson&#x2019;s disease. J. Parkinsons Dis. 2021;11:31&#x2013;43. doi: 10.3233/JPD-202279.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JPD-202279</ArticleId><ArticleId IdType="pmc">PMC7990414</ArticleId><ArticleId IdType="pubmed">33361610</ArticleId></ArticleIdList></Reference><Reference><Citation>Casals J., Elizan T.S., Yahr M.D. Postencephalitic parkinsonism&#x2014;A review. J. Neural. Transm. 1998;105:645&#x2013;676. doi: 10.1007/s007020050086.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s007020050086</ArticleId><ArticleId IdType="pubmed">9826109</ArticleId></ArticleIdList></Reference><Reference><Citation>Krusz J.C., Koller W.C., Ziegler D.K. Historical review: Abnormal movements associated with epidemic encephalitis lethargica. Mov. Disord. 1987;2:137&#x2013;141. doi: 10.1002/mds.870020301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.870020301</ArticleId><ArticleId IdType="pubmed">3332913</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffman L.A., Vilensky J.A. Encephalitis lethargica: 100 years after the epidemic. Brain. 2017;140:2246&#x2013;2251. doi: 10.1093/brain/awx177.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awx177</ArticleId><ArticleId IdType="pubmed">28899018</ArticleId></ArticleIdList></Reference><Reference><Citation>Cadar D., Jellinger K.A., Riederer P., Strobel S., Monoranu C.M., Tappe D. No metagenomics evidence of causative viral pathogens in postencephalitic parkinsonism following encephalitis lethargica. Microrganisms. 2021;9:1716. doi: 10.3390/microorganisms9081716.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9081716</ArticleId><ArticleId IdType="pmc">PMC8398509</ArticleId><ArticleId IdType="pubmed">34442795</ArticleId></ArticleIdList></Reference><Reference><Citation>Leta V., Urso D., Batzu L., Lau Y.H., Mathew D., Boura I., Raeder V., Falup-Pecurariu C., van Wamelen D., Ray Chaudhuri K. Viruses, parkinsonism and Parkinson&#x2019;s disease: The past, present and future. J. Neural. Transm. 2022;129:1119&#x2013;1132. doi: 10.1007/s00702-022-02536-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-022-02536-y</ArticleId><ArticleId IdType="pmc">PMC9422946</ArticleId><ArticleId IdType="pubmed">36036863</ArticleId></ArticleIdList></Reference><Reference><Citation>Jang H., Boltz D.A., Webster R.G., Smeyne R.J. Viral Parkinsonism. Biochim. Biophys. Acta. 2009;1792:714&#x2013;721. doi: 10.1016/j.bbadis.2008.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2008.08.001</ArticleId><ArticleId IdType="pmc">PMC4642437</ArticleId><ArticleId IdType="pubmed">18760350</ArticleId></ArticleIdList></Reference><Reference><Citation>Bopeththa B.V.K.M., Ralapanawa U. Post encephalic parkinsonism following dengue viral infection. BMC Res. Notes. 2017;10:655. doi: 10.1186/s13104-017-2954-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13104-017-2954-5</ArticleId><ArticleId IdType="pmc">PMC5708097</ArticleId><ArticleId IdType="pubmed">29187231</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan J., Lu Z., Zhou Q. Reversible parkinsonism due to involvement of substantia nigra in Epstein-Barr virus encephalitis. Mov. Disord. 2012;27:156&#x2013;157. doi: 10.1002/mds.23935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.23935</ArticleId><ArticleId IdType="pubmed">21989835</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradhan S., Pandey N., Shashank S., Gupta R.K., Mathur A. Parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis. Neurology. 1999;53:1782&#x2013;1786. doi: 10.1212/WNL.53.8.1781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.53.8.1781</ArticleId><ArticleId IdType="pubmed">10563628</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasha S.A., Pasha S.A., Suhasini T., Rao D.A. Hepatitis E virus-associated acute encephalitic Parkinsonism. J. Assoc. Physicians India. 2018;66:92&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">30341882</ArticleId></ArticleIdList></Reference><Reference><Citation>Leta V., Boura I., van Wamelan D.J., Rodriguez-Violante M., Antonini A., Chaudhuri K.R. COVID-19 and Parkinson&#x2019;s disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism. Int. Rev. Neurobiol. 2022;165:63&#x2013;89. doi: 10.1016/bs.irn.2022.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.irn.2022.04.004</ArticleId><ArticleId IdType="pmc">PMC9357514</ArticleId><ArticleId IdType="pubmed">36208907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellul M.A., Benjamin L., Singh B., Lant S., Michael B.D., Easton A., Kneen R., Defres S., Sejvar J., Solomon T. Neurological associations of COVID-19. Lancet Neurol. 2020;19:767&#x2013;783. doi: 10.1016/S1474-4422(20)30221-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30221-0</ArticleId><ArticleId IdType="pmc">PMC7332267</ArticleId><ArticleId IdType="pubmed">32622375</ArticleId></ArticleIdList></Reference><Reference><Citation>Morassi M., Palmerini F., Nici S., Magni E., Savelli G., Guerra U.P., Chieregato M., Morbelli S., Vogrig A. SARS-CoV-2-related encephalitis with prominent parkinsonism: Clinical and FDG-PET correlates in two patients. J. Neurol. 2021;268:3980&#x2013;3987. doi: 10.1007/s00415-021-10560-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-021-10560-3</ArticleId><ArticleId IdType="pmc">PMC8059684</ArticleId><ArticleId IdType="pubmed">33884450</ArticleId></ArticleIdList></Reference><Reference><Citation>Jellinger K.A. Absence of alpha-synuclein pathology in postencephalitic parkinsonism. Acta Neuropathol. 2009;118:371&#x2013;379. doi: 10.1007/s00401-009-0537-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-009-0537-9</ArticleId><ArticleId IdType="pubmed">19404653</ArticleId></ArticleIdList></Reference><Reference><Citation>Brydon L., Harrison N.A., Walker C., Steptoe A., Critchley H.D. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol. Psychiatry. 2008;63:1022&#x2013;1029. doi: 10.1016/j.biopsych.2007.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2007.12.007</ArticleId><ArticleId IdType="pmc">PMC2885493</ArticleId><ArticleId IdType="pubmed">18242584</ArticleId></ArticleIdList></Reference><Reference><Citation>Capuron L., Pagnoni G., Demetrashvili M.F., Lawson D.H., Fornwalt F.B., Woolwine B., Berns G.S., Nemeroff C.B., Miller A.H. Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology. 2007;32:2384&#x2013;2392. doi: 10.1038/sj.npp.1301362.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.npp.1301362</ArticleId><ArticleId IdType="pubmed">17327884</ArticleId></ArticleIdList></Reference><Reference><Citation>Capuron L., Pagnoni G., Drake D.F., Woolwine B.J., Spivey J.R., Crowe R.J., Votaw J.R., Goodman M.M., Miller A.H. Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch. Gen. Psychiatry. 2012;69:1044&#x2013;1053. doi: 10.1001/archgenpsychiatry.2011.2094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archgenpsychiatry.2011.2094</ArticleId><ArticleId IdType="pmc">PMC3640298</ArticleId><ArticleId IdType="pubmed">23026954</ArticleId></ArticleIdList></Reference><Reference><Citation>Majer M., Welberg L.A.M., Capuron L., Pagnoni G., Raison C.L., Miller A.H. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav. Immun. 2008;22:870&#x2013;880. doi: 10.1016/j.bbi.2007.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2007.12.009</ArticleId><ArticleId IdType="pmc">PMC2497339</ArticleId><ArticleId IdType="pubmed">18258414</ArticleId></ArticleIdList></Reference><Reference><Citation>Capuron L., Dantzer R. Cytokines and depression: The need for a new paradigm. Brain Behav. Immun. 2003;17((Suppl. 1)):S119&#x2013;S124. doi: 10.1016/S0889-1591(02)00078-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0889-1591(02)00078-8</ArticleId><ArticleId IdType="pubmed">12615197</ArticleId></ArticleIdList></Reference><Reference><Citation>Raison C.L., Borison A.V., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: Relationship to monoamines and depression. Biol. Psychiatry. 2009;65:296&#x2013;303. doi: 10.1016/j.biopsych.2008.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopsych.2008.08.010</ArticleId><ArticleId IdType="pmc">PMC2655138</ArticleId><ArticleId IdType="pubmed">18801471</ArticleId></ArticleIdList></Reference><Reference><Citation>Felger J.C., Li Z., Haroon E., Woolwine B.J., Jung M.Y., Hu X., Miller A.H. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Mol. Psychiatry. 2016;21:1358&#x2013;1365. doi: 10.1038/mp.2015.168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mp.2015.168</ArticleId><ArticleId IdType="pmc">PMC4862934</ArticleId><ArticleId IdType="pubmed">26552591</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldsmith D.R., Haroon E., Woolwine B.J., Jung M.Y., Wommack E.C., Harvey P.D., Treadway M.T., Felger J.C., Miller A.H. Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain Behav. Immun. 2016;56:281&#x2013;288. doi: 10.1016/j.bbi.2016.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2016.03.025</ArticleId><ArticleId IdType="pmc">PMC4939278</ArticleId><ArticleId IdType="pubmed">27040122</ArticleId></ArticleIdList></Reference><Reference><Citation>Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., Bauer J., Lieb K. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology. 2000;152:383&#x2013;389. doi: 10.1007/s002130000549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002130000549</ArticleId><ArticleId IdType="pubmed">11140330</ArticleId></ArticleIdList></Reference><Reference><Citation>Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., Chaly T., Robeson W., Margouleff D., Przedborski S. The metabolic topography of parkinsonism. J. Cereb. Blood Flow Metab. 1994;14:783&#x2013;801. doi: 10.1038/jcbfm.1994.99.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/jcbfm.1994.99</ArticleId><ArticleId IdType="pubmed">8063874</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentis M.J., McIntosh A.R., Perrine K., Dhawan V., Berlin B., Feigin A., Edwards C., Mattis P., Eidelberg D. Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson&#x2019;s disease. Am. J Psychiatry. 2002;159:746&#x2013;754. doi: 10.1176/appi.ajp.159.5.746.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.159.5.746</ArticleId><ArticleId IdType="pubmed">11986127</ArticleId></ArticleIdList></Reference><Reference><Citation>Spetsieris P.G., Moeller J.R., Dhawan V., Ishikawa T., Eidelberg D. Visualizing the evolution of abnormal metabolic networks in the brain using PET. Comput. Med. Imaging Graph. 1995;19:295&#x2013;306. doi: 10.1016/0895-6111(95)00011-E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0895-6111(95)00011-E</ArticleId><ArticleId IdType="pubmed">7641174</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann T., DeLong M.R. Oscillations in the basal ganglia. Nature. 1999;400:621&#x2013;622. doi: 10.1038/23148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/23148</ArticleId><ArticleId IdType="pubmed">10458157</ArticleId></ArticleIdList></Reference><Reference><Citation>Reite M., Laudenslager M., Jones J., Crnic L., Kaemingk K. Interferon decreases REM latency. Biol. Psychiatry. 1987;22:104&#x2013;107. doi: 10.1016/0006-3223(87)90136-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-3223(87)90136-3</ArticleId><ArticleId IdType="pubmed">3790631</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosti&#x107; V.S., Susi&#x107; V., Covickovi&#x107;-Sterni&#x107; N., Marinkovi&#x107; Z., Jankovi&#x107; S. Reduced rapid eye movement sleep latency in patients with Parkinson&#x2019;s disease. J. Neurol. 1989;236:421&#x2013;423. doi: 10.1007/BF00314903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00314903</ArticleId><ArticleId IdType="pubmed">2809645</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumakura Y., Cumming P. PET studies of cerebral levodopa metabolism: A review of clinical findings and modeling approaches. Neuroscientist. 2009;15:635&#x2013;650. doi: 10.1177/1073858409338217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073858409338217</ArticleId><ArticleId IdType="pubmed">19793723</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumakura Y., Gjedde A., Danielsen E.H., Christensen S., Cumming P. Dopamine storage capacity in caudate and putamen of patients with early Parkinson&#x2019;s disease: Correlation with asymmetry of motor symptoms. J. Cereb. Blood Flow Metab. 2006;26:358&#x2013;370. doi: 10.1038/sj.jcbfm.9600202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sj.jcbfm.9600202</ArticleId><ArticleId IdType="pubmed">16079784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bersano A., Aghemo A., Rumi M.G., Ballabio E., Candelise L., Colombo M. Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism. Eur. J. Intern. Med. 2008;19:370&#x2013;371. doi: 10.1016/j.ejim.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejim.2007.10.003</ArticleId><ArticleId IdType="pubmed">18549943</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarasombath P., Sumida K., Kaku D.A. Parkinsonism associated with interferon alpha therapy for chronic myelogenous leukemia. Hawaii Med. J. 2002;61:57.</Citation><ArticleIdList><ArticleId IdType="pubmed">11965836</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>